Zoldonrasib and daraxonrasib versus chemotherapy for first treatment of metastatic KRAS G12D pancreatic cancer
Compares zoldonrasib with daraxonrasib against chemotherapy in newly treated metastatic KRAS G12D pancreatic cancer.
Key facts
- Who runs it
- Revolution Medicines, Inc.
- Where
- Jacksonville, Phoenix, Providence, Rochester, Scottsdale, and Tampa, United StatesSee the 6 sites
- Trial code
- Registry title
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 400 people, planned
- Started
- 28 Aug 2026
- Expected to end
- Apr 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- daraxonrasib
- gemcitabine
- nab-paclitaxel
- zoldonrasib
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic pancreatic adenocarcinoma with a KRAS G12D mutation who have not yet had treatment for advanced disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Pancreatic adenocarcinoma (including adenosquamous carcinoma) that has spread (metastatic), diagnosed as metastatic no more than 6 weeks before consent, with disease that can be measured (RECIST v1.1).
- Earlier treatment
- No earlier treatment for locally advanced unresectable or metastatic disease. No earlier MAPK-pathway targeted therapy or RAS-targeted vaccine in the metastatic setting.
- Biomarker or test result
- A documented KRAS G12D mutation.
Main reasons for not taking part
- Known driver mutations that have approved targeted therapies
- Acinar cell carcinoma, pancreatic neuroendocrine tumors or other non-adenocarcinoma pancreatic cancers
- Active or known untreated cancer spread to the brain or its linings (central nervous system or leptomeningeal disease)
- Conditions that affect taking or absorbing the study drug
- Major surgery within 28 days before randomization
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- At least 18 years old and has provided informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally advanced unresectable or metastatic setting
- No prior treatment in the locally advanced unresectable or metastatic setting
- Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent
- Documented KRAS G12D mutation status
- Measurable disease per RECIST v1.1
- Adequate organ function (bone marrow, liver, kidney, coagulation)
Who cannot take part
- Mutation status with known driver mutations for which there are approved targeted therapies
- Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting
- Major surgery within 28 days prior to randomization
- Acinar cell carcinoma, pancreatic neuroendocrine tumors, tumors involving islet cells or islet cell neoplasms, and other non-adenocarcinoma pancreatic malignancies
- Active or known history of untreated central nervous system metastatic or leptomeningeal disease
- Any conditions that may affect the ability to take or absorb study drug
- Tumors determined to originate from non-pancreatic primary sites
- Patient is unable or unwilling to comply with protocol-required study visits or procedures
- Additional inclusion \& exclusion criteria may apply
Where in United States
- Mayo Clinic FloridaJacksonville, United StatesContact: Hani M. BabikerTaking people
- Mayo Clinic - ArizonaPhoenix, United StatesContact: Tanios S. Bekaii-SaabTaking people
- Rhode Island HospitalProvidence, United StatesContact: Andrew SchumacherTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: Ben GeorgeTaking people
- HonorHealth Research InstituteScottsdale, United StatesContact: Amy MalensekTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Cheyenne SchneiderTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
The 2 groups in the trial
- Arm A: daraxonrasib + zoldonrasibTreatment being tested
combination of study drugs
Treatment: daraxonrasib and zoldonrasib
- Arm B: gemcitabine and nab-paclitaxelTreatment being tested
chemotherapy
Treatment: gemcitabine and nab-paclitaxel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Plain-language title
- Zoldonrasib and daraxonrasib versus chemotherapy for first treatment of metastatic KRAS G12D pancreatic cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026